Spots Global Cancer Trial Database for flt3
Every month we try and update this database with for flt3 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations | NCT01522469 | Relapsed or Ref... | Crenolanib Besy... | 18 Years - | Arog Pharmaceuticals, Inc. | |
| A Study of CPX-351 (Vyxeosâą) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia | NCT04209725 | Leukemia, Myelo... | CPX-351 Quizartinib | 18 Years - 80 Years | SCRI Development Innovations, LLC | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies | NCT05279859 | Acute Myeloid L... | ERAS-007 ERAS-601 Gilteritinib | 18 Years - 99 Years | Erasca, Inc. | |
| A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy | NCT02752035 | Acute Myeloid L... Acute Myeloid L... | gilteritinib azacitidine | 18 Years - | Astellas Pharma Inc | |
| Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia | NCT03836209 | Acute Myeloid L... | Gilteritinib Midostaurin Daunorubicin Cytarabine | 18 Years - 70 Years | PrECOG, LLC. | |
| A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML | NCT03280030 | Acute Myeloid L... | Midostaurin Placebo | 18 Years - 70 Years | Novartis | |
| A Study of CPX-351 (Vyxeosâą) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia | NCT04209725 | Leukemia, Myelo... | CPX-351 Quizartinib | 18 Years - 80 Years | SCRI Development Innovations, LLC | |
| Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy | NCT02624570 | Acute Myeloid L... FLT3 Mutation, ... | Midostaurin | 18 Years - | Novartis | |
| A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) | NCT03730012 | Acute Myeloid L... Acute Myeloid L... | gilteritinib atezolizumab | 18 Years - | Astellas Pharma Inc | |
| Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib | NCT01831726 | Tumor Pathway A... | Dovitinib (TKI2... | 18 Years - 100 Years | Novartis | |
| GM-CLAG in Relapsed/Refractory FLT3-mutated AML | NCT05330377 | Acute Myeloid L... | Gilteritinib 40... Cladribine Cytarabine Filgrastim Mitoxantrone | 18 Years - | University of Kentucky | |
| Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years | NCT00783653 | Acute Myeloid L... | Sunitinib | 60 Years - | UniversitÀtsklinikum Hamburg-Eppendorf | |
| A Phase 1, Study of BMF-500 in Adults With Acute Leukemia | NCT05918692 | Acute Myeloid L... Acute Lymphobla... Acute Mixed-Phe... | BMF-500 | 18 Years - | Biomea Fusion Inc. | |
| A Phase 1, Study of BMF-500 in Adults With Acute Leukemia | NCT05918692 | Acute Myeloid L... Acute Lymphobla... Acute Mixed-Phe... | BMF-500 | 18 Years - | Biomea Fusion Inc. | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies | NCT05279859 | Acute Myeloid L... | ERAS-007 ERAS-601 Gilteritinib | 18 Years - 99 Years | Erasca, Inc. | |
| A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations | NCT01657682 | Acute Myeloid L... | Crenolanib besy... | 18 Years - | Arog Pharmaceuticals, Inc. | |
| Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML) | NCT00989261 | Acute Myeloid L... | Compound AC220 | 18 Years - 85 Years | Daiichi Sankyo | |
| Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia. | NCT03379727 | Acute Myeloid L... | Midostaurin Cytarabine anthracycline (... | 18 Years - | Novartis | |
| GM-CLAG in Relapsed/Refractory FLT3-mutated AML | NCT05330377 | Acute Myeloid L... | Gilteritinib 40... Cladribine Cytarabine Filgrastim Mitoxantrone | 18 Years - | University of Kentucky | |
| Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML | NCT00373373 | Acute Myeloid L... | Sorafenib Placebo | 61 Years - | University Hospital Muenster | |
| A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS | NCT04477291 | Acute Myeloid L... Myelodysplastic... | CG-806 | 18 Years - | Aptose Biosciences Inc. | |
| Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT00915252 | Acute Myeloid L... | azacitidine standard chemot... | 61 Years - | University Hospital Muenster | |
| Development of a Diagnostic Kit for FLT3-ITD in Acute Myeloid Leukemia | NCT01141673 | Acute Myeloid L... | - | Taipei Medical University WanFang Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
